Replies to post #109677 on Biotech Values

[DewDiligence]

The [GSK] spokesperson mentioned…SRT2104 and SRT2379 as drugs similar to SRT501 that the company is developing.

If we accept this comment at face value, the sirtuin approach per se is not yet dead.

[drbio45]

According to a GlaxoSmithKline spokesperson, an internal analysis of the kidney failure cases has concluded that they “most likely were due to the underlying disease … However, the formulation of SRT501 was not well tolerated, and side effects of nausea / vomiting / diarrhea may have indirectly led to dehydration, which exacerbated the development of the acute [kidney] failure.”

from those side effects it appears that it should be inlicensed by a small biotech company and put immediately in obesity trials.